Search
epcoritamab-bysb (Epkinly)
Indications:
- treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
Dosage:
- cycle 1
- day 1: 0.16 mg
- day 8: 0.8 mg
- day 15: 48 mg (full dose) hospitalize for 24 hr after 1st full dose on day 15
- day 22: 48 mg
- cycles 2 & 3
- days 1, 8, 15, & 22: 48 mg
- cycles 4-9
- days 1 & 15: 48 mg
- cycles >= 10
- day 1: 48 mg
* cycle = 28 days
Adverse effects:
- > 20%
- cytokine release syndrome,
- fatigue
- musculoskeletal pain, abdominal pain
- injection site reactions
- pyrexia, nausea, diarrhea.
- > 10%
- leukopenia, neutropenia, lymphopenia, anemia, thrombocytopenia
Mechanism of action:
- bispecific CD20-directed CD3 T-cell engager
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Wikipedia: Epcoritamab
https://en.wikipedia.org/wiki/Epcoritamab
- HIGHLIGHTS OF PRESCRIBING INFORMATION
EPKINLY (epcoritamab-bysp) injection, for subcutaneous use
https://www.genmab-pi.com/prescribing-information/epkinly-pi.pdf